Demographics and screening characteristics for ≥1-year studies in patients with COPD by baseline blood eosinophil level and treatment group: SCO30002
| Characteristic | FP/SAL | FP | Placebo | |||
|---|---|---|---|---|---|---|
| <2% | ≥2% | <2% | ≥2% | <2% | ≥2% | |
| n | 45 | 84 | 50 | 74 | 50 | 70 |
| Age, mean (SD) | 64.4 (9.08) | 63.7 (10.50) | 63.0 (9.44) | 65.1 (8.13) | 66.9 (9.02) | 64.7 (8.62) |
| Male (%) | 87 | 82 | 84 | 81 | 74 | 84 |
| Current smokers (%) | 47 | 40 | 52 | 39 | 38 | 34 |
| Pack-years, median (range) | 37.5 (10–90)* | 35.0 (10–300) | 30.5 (10–150) | 38.8 (10–300) | 39.0 (10–88) | 30.0 (10–108) |
| Post-BD FEV1% predicted, mean (SD) | 55.3 (11.20) | 56.9 (14.07) | 56.5 (11.38) | 57.5 (13.46)† | 55.6 (9.48) | 56.2 (12.06) |
| FEV1% reversibility, mean (SD) | 3.4 (3.06) | 2.6 (4.22) | 2.8 (3.49) | 3.6 (3.90)† | 3.5 (3.50) | 3.5 (3.59) |
| Moderate/severe exacerbations in prior 12 months, n (%) | ||||||
| 0 | 17 (38) | 23 (28)‡ | 19 (38) | 27 (36) | 18 (36) | 29 (41) |
| 1 | 9 (20) | 22 (27)‡ | 10 (20) | 14 (19) | 9 (18) | 14 (20) |
| 2 | 8 (18) | 20 (24)‡ | 11 (22) | 16 (22) | 10 (20) | 17 (24) |
| >2 | 11 (24) | 18 (22)‡ | 10 (20) | 17 (23) | 13 (26) | 10 (14) |
*n=43.
†n=73.
‡n=83.
BD, bronchodilator; FP, fluticasone propionate; SAL, salmeterol.